quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:41:23·888d
NEWSRelease
Timber Pharmaceuticals Inc. logo

Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy; Timber Pharmaceuticals, Inc. Lists Both Assets And Liabilities In Range Of $1M-$10M

TMBR· Timber Pharmaceuticals Inc.
Health Care
Original source

Companies

  • TMBR
    Timber Pharmaceuticals Inc.
    Health Care

Related

  • SEC818d
    Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • SEC822d
    Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership
  • SEC853d
    Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • NEWS876d
    Timber Pharmaceuticals Reveals Commencement Of NYSE American Delisting Proceedings: Common Stock Expected To Begin Trading On OTC Market
  • PR876d
    Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
  • SEC876d
    SEC Form 25-NSE filed by Timber Pharmaceuticals Inc.
  • SEC877d
    Timber Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
  • NEWS877d
    Timber Pharmaceuticals Receives Court Approval Of All "First Day" Motions To Support Business Operations & Discloses Communication From NYSE American
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022